Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1998 Aug;78(3):413–418. doi: 10.1038/bjc.1998.508

The effect of finasteride on the prostate gland in men with elevated serum prostate-specific antigen levels.

R J Cote 1, E C Skinner 1, C E Salem 1, S J Mertes 1, F Z Stanczyk 1, B E Henderson 1, M C Pike 1, R K Ross 1
PMCID: PMC2063039  PMID: 9703292

Abstract

Prostate cancer is a disease associated with androgens. It has been hypothesized that reducing the conversion of testosterone (T) to dihydrotestosterone (DHT) in the prostate by the use of the drug finasteride, a 5alpha-reductase inhibitor, will reduce the incidence of prostate cancer. We investigated the chemopreventive potential of finasteride by evaluating its effect on the prostate gland of men with elevated serum prostate-specific antigen (PSA). Fifty-two men with elevated PSA and prostate sextant biopsies negative for cancer were randomized to receive finasteride 5 mg day(-1) (27 patients) or no medication (25 patients) for 12 months and were rebiopsied at 12 months. The biopsies were evaluated for the presence of cancer, the proportion of glandular and hyperplastic tissue, and the presence of high-grade prostatic intraepithelial neoplasia (PIN). Epithelial proliferation was assessed in the prestudy and 12-month biopsies by immunohistochemistry using antibody to proliferating cell nuclear antigen (PCNA). Serum blood samples were drawn at baseline and after 1, 3, 6 and 12 months of study. In the control group, serum levels of PSA and T were unchanged throughout the 12 months. In the finasteride group, PSA decreased 48% (P < 0.001), DHT decreased 67% (P < 0.001) and T increased 21% (P < 0.001). Histological evaluation of prestudy and 12-month biopsy specimens revealed that the finasteride group had a 30% reduction in the percentage of hyperplastic epithelial tissue (P = 0.002), although this decrease was not statistically significantly different between the finasteride and control groups (P = 0.11). In patients with PIN on prestudy biopsy, no change occurred in the PIN lesions with finasteride treatment. Finasteride also had no effect on the proliferation index of prostatic epithelial cells. Of the 27 patients treated with finasteride, eight (30%) had adenocarcinoma of the prostate detected on the 12-month biopsy, compared with one (4%) of the control patients (P = 0.025). In the treatment group, six cancers occurred in the eight patients with PIN on the prestudy biopsy; in the observation group no cancers were detected in the five patients with PIN on the prestudy biopsy (P = 0.021). Two cancers occurred in the 19 men in the treatment group with no evidence of PIN on the prestudy biopsy, compared with one cancer in the 20 men in the observation group with no evidence of PIN on the prestudy biopsy (P = 0.60). This study, using a novel model for evaluating short-term efficacy of chemopreventive or therapeutic agents in men at high risk of prostate cancer, provides little evidence that finasteride is an effective chemopreventive agent for prostate cancer in men with elevated PSA.

Full text

PDF
413

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andersen J. T., Ekman P., Wolf H., Beisland H. O., Johansson J. E., Kontturi M., Lehtonen T., Tveter K. Can finasteride reverse the progress of benign prostatic hyperplasia? A two-year placebo-controlled study. The Scandinavian BPH Study Group. Urology. 1995 Nov;46(5):631–637. doi: 10.1016/s0090-4295(99)80291-x. [DOI] [PubMed] [Google Scholar]
  2. Brawer M. K. Prostatic intraepithelial neoplasia: a premalignant lesion. Hum Pathol. 1992 Mar;23(3):242–248. doi: 10.1016/0046-8177(92)90104-b. [DOI] [PubMed] [Google Scholar]
  3. Brooks J. R., Baptista E. M., Berman C., Ham E. A., Hichens M., Johnston D. B., Primka R. L., Rasmusson G. H., Reynolds G. F., Schmitt S. M. Response of rat ventral prostate to a new and novel 5 alpha-reductase inhibitor. Endocrinology. 1981 Sep;109(3):830–836. doi: 10.1210/endo-109-3-830. [DOI] [PubMed] [Google Scholar]
  4. Brooks J. R., Berman C., Nguyen H., Prahalada S., Primka R. L., Rasmusson G. H., Slater E. E. Effect of castration, DES, flutamide, and the 5 alpha-reductase inhibitor, MK-906, on the growth of the Dunning rat prostatic carcinoma, R-3327. Prostate. 1991;18(3):215–227. doi: 10.1002/pros.2990180304. [DOI] [PubMed] [Google Scholar]
  5. GLANTZ G. M. CIRRHOSIS AND CARCINOMA OF THE PROSTATE GLAND. J Urol. 1964 Mar;91:291–293. doi: 10.1016/S0022-5347(17)64110-7. [DOI] [PubMed] [Google Scholar]
  6. Geller J. Five-year follow-up of patients with benign prostatic hyperplasia treated with finasteride. Eur Urol. 1995;27(4):267–273. doi: 10.1159/000475179. [DOI] [PubMed] [Google Scholar]
  7. Gormley G. J., Stoner E., Bruskewitz R. C., Imperato-McGinley J., Walsh P. C., McConnell J. D., Andriole G. L., Geller J., Bracken B. R., Tenover J. S. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med. 1992 Oct 22;327(17):1185–1191. doi: 10.1056/NEJM199210223271701. [DOI] [PubMed] [Google Scholar]
  8. Gould V. E., Doljanskaia V., Gooch G., Bostwick D. G. Immunolocalization of glycoprotein A-80 in prostatic carcinoma and prostatic intraepithelial neoplasia. Hum Pathol. 1996 Jun;27(6):547–552. doi: 10.1016/s0046-8177(96)90160-4. [DOI] [PubMed] [Google Scholar]
  9. Grino P. B., Griffin J. E., Wilson J. D. Testosterone at high concentrations interacts with the human androgen receptor similarly to dihydrotestosterone. Endocrinology. 1990 Feb;126(2):1165–1172. doi: 10.1210/endo-126-2-1165. [DOI] [PubMed] [Google Scholar]
  10. Hall P. A., Levison D. A., Woods A. L., Yu C. C., Kellock D. B., Watkins J. A., Barnes D. M., Gillett C. E., Camplejohn R., Dover R. Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasms. J Pathol. 1990 Dec;162(4):285–294. doi: 10.1002/path.1711620403. [DOI] [PubMed] [Google Scholar]
  11. Imperato-McGinley J., Guerrero L., Gautier T., Peterson R. E. Steroid 5alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science. 1974 Dec 27;186(4170):1213–1215. doi: 10.1126/science.186.4170.1213. [DOI] [PubMed] [Google Scholar]
  12. Keetch D. W., Catalona W. J., Smith D. S. Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. J Urol. 1994 Jun;151(6):1571–1574. doi: 10.1016/s0022-5347(17)35304-1. [DOI] [PubMed] [Google Scholar]
  13. Lamb J. C., English H., Levandoski P. L., Rhodes G. R., Johnson R. K., Isaacs J. T. Prostatic involution in rats induced by a novel 5 alpha-reductase inhibitor, SK&F 105657: role for testosterone in the androgenic response. Endocrinology. 1992 Feb;130(2):685–694. doi: 10.1210/endo.130.2.1733716. [DOI] [PubMed] [Google Scholar]
  14. Lepor H., Williford W. O., Barry M. J., Brawer M. K., Dixon C. M., Gormley G., Haakenson C., Machi M., Narayan P., Padley R. J. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N Engl J Med. 1996 Aug 22;335(8):533–539. doi: 10.1056/NEJM199608223350801. [DOI] [PubMed] [Google Scholar]
  15. Lookingbill D. P., Demers L. M., Wang C., Leung A., Rittmaster R. S., Santen R. J. Clinical and biochemical parameters of androgen action in normal healthy Caucasian versus Chinese subjects. J Clin Endocrinol Metab. 1991 Jun;72(6):1242–1248. doi: 10.1210/jcem-72-6-1242. [DOI] [PubMed] [Google Scholar]
  16. McNeal J. E., Bostwick D. G. Intraductal dysplasia: a premalignant lesion of the prostate. Hum Pathol. 1986 Jan;17(1):64–71. doi: 10.1016/s0046-8177(86)80156-3. [DOI] [PubMed] [Google Scholar]
  17. McNeal J. E. Origin and development of carcinoma in the prostate. Cancer. 1969 Jan;23(1):24–34. doi: 10.1002/1097-0142(196901)23:1<24::aid-cncr2820230103>3.0.co;2-1. [DOI] [PubMed] [Google Scholar]
  18. Noble R. L. The development of prostatic adenocarcinoma in Nb rats following prolonged sex hormone administration. Cancer Res. 1977 Jun;37(6):1929–1933. [PubMed] [Google Scholar]
  19. Norman R. W., Coakes K. E., Wright A. S., Rittmaster R. S. Androgen metabolism in men receiving finasteride before prostatectomy. J Urol. 1993 Nov;150(5 Pt 2):1736–1739. doi: 10.1016/s0022-5347(17)35882-2. [DOI] [PubMed] [Google Scholar]
  20. Pocock S. J., Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics. 1975 Mar;31(1):103–115. [PubMed] [Google Scholar]
  21. Presti J. C., Jr, Fair W. R., Andriole G., Sogani P. C., Seidmon E. J., Ferguson D., Ng J., Gormley G. J. Multicenter, randomized, double-blind, placebo controlled study to investigate the effect of finasteride (MK-906) on stage D prostate cancer. J Urol. 1992 Oct;148(4):1201–1204. doi: 10.1016/s0022-5347(17)36860-x. [DOI] [PubMed] [Google Scholar]
  22. Preston-Martin S., Pike M. C., Ross R. K., Jones P. A., Henderson B. E. Increased cell division as a cause of human cancer. Cancer Res. 1990 Dec 1;50(23):7415–7421. [PubMed] [Google Scholar]
  23. Ross R. K., Bernstein L., Lobo R. A., Shimizu H., Stanczyk F. Z., Pike M. C., Henderson B. E. 5-alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet. 1992 Apr 11;339(8798):887–889. doi: 10.1016/0140-6736(92)90927-u. [DOI] [PubMed] [Google Scholar]
  24. Ross R. K., McCurtis J. W., Henderson B. E., Menck H. R., Mack T. M., Martin S. P. Descriptive epidemiology of testicular and prostatic cancer in Los Angeles. Br J Cancer. 1979 Mar;39(3):284–292. doi: 10.1038/bjc.1979.53. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Ross R., Bernstein L., Judd H., Hanisch R., Pike M., Henderson B. Serum testosterone levels in healthy young black and white men. J Natl Cancer Inst. 1986 Jan;76(1):45–48. [PubMed] [Google Scholar]
  26. Salem C. E., Tomasic N. A., Elmajian D. A., Esrig D., Nichols P. W., Taylor C. R., Skinner D. G., Roy-Burman P., Lieskovsky G., Cote R. J. p53 protein and gene alterations in pathological stage C prostate carcinoma. J Urol. 1997 Aug;158(2):510–514. [PubMed] [Google Scholar]
  27. Shi S. R., Key M. E., Kalra K. L. Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem. 1991 Jun;39(6):741–748. doi: 10.1177/39.6.1709656. [DOI] [PubMed] [Google Scholar]
  28. Stoner E., Round E., Ferguson D., Gormley G. J. Clinical experience of the detection of prostate cancer in patients with benign prostate hyperplasia treated with finasteride. The Finasteride Study Group. J Urol. 1994 May;151(5):1296–1300. doi: 10.1016/s0022-5347(17)35235-7. [DOI] [PubMed] [Google Scholar]
  29. Stoner E. Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. Urology. 1994 Mar;43(3):284–294. doi: 10.1016/0090-4295(94)90068-x. [DOI] [PubMed] [Google Scholar]
  30. Taylor C. R., Shi S. R., Chaiwun B., Young L., Imam S. A., Cote R. J. Strategies for improving the immunohistochemical staining of various intranuclear prognostic markers in formalin-paraffin sections: androgen receptor, estrogen receptor, progesterone receptor, p53 protein, proliferating cell nuclear antigen, and Ki-67 antigen revealed by antigen retrieval techniques. Hum Pathol. 1994 Mar;25(3):263–270. doi: 10.1016/0046-8177(94)90198-8. [DOI] [PubMed] [Google Scholar]
  31. Tempany C. M., Partin A. W., Zerhouni E. A., Zinreich S. J., Walsh P. C. The influence of finasteride on the volume of the peripheral and periurethral zones of the prostate in men with benign prostatic hyperplasia. Prostate. 1993;22(1):39–42. doi: 10.1002/pros.2990220106. [DOI] [PubMed] [Google Scholar]
  32. Tutrone R. F., Jr, Ball R. A., Ornitz D. M., Leder P., Richie J. P. Benign prostatic hyperplasia in a transgenic mouse: a new hormonally sensitive investigatory model. J Urol. 1993 Mar;149(3):633–639. doi: 10.1016/s0022-5347(17)36169-4. [DOI] [PubMed] [Google Scholar]
  33. Umekita Y., Hiipakka R. A., Kokontis J. M., Liao S. Human prostate tumor growth in athymic mice: inhibition by androgens and stimulation by finasteride. Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11802–11807. doi: 10.1073/pnas.93.21.11802. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Walsh P. C., Madden J. D., Harrod M. J., Goldstein J. L., MacDonald P. C., Wilson J. D. Familial incomplete male pseudohermaphroditism, type 2. Decreased dihydrotestosterone formation in pseudovaginal perineoscrotal hypospadias. N Engl J Med. 1974 Oct 31;291(18):944–949. doi: 10.1056/NEJM197410312911806. [DOI] [PubMed] [Google Scholar]
  35. Waseem N. H., Lane D. P. Monoclonal antibody analysis of the proliferating cell nuclear antigen (PCNA). Structural conservation and the detection of a nucleolar form. J Cell Sci. 1990 May;96(Pt 1):121–129. doi: 10.1242/jcs.96.1.121. [DOI] [PubMed] [Google Scholar]
  36. Wilson J. D. Sexual differentiation of the gonads and of the reproductive tract. Biol Neonate. 1989;55(6):322–330. doi: 10.1159/000242936. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES